Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01923181
Recruitment Status : Completed
First Posted : August 15, 2013
Last Update Posted : February 1, 2018
Information provided by (Responsible Party):
Novo Nordisk A/S

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 11, 2014
  Actual Study Completion Date : December 11, 2014
  Certification/Extension First Submitted : March 30, 2017